Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical United States Reimbursement

Drug Price Control Proposals Pared Down In Democrats’ Draft Platform

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Draft includes only a selection of price control policies that have been offered by presumptive nominee Hillary Clinton and candidate Sen. Bernie Sanders on the campaign trail.

You may also be interested in...



Dems' 'Better Deal' Would Create Drug Price Gouging 'Enforcer'

Plan would empower new agency to investigate and potentially fine drug manufacturers that make unjustified price increases.

Clinton Transition Team Includes Tanden, Underscoring Rx Pricing Focus

Center for American Progress President Neera Tanden has actively advocated Clinton’s position on prescription drug price controls over the past year.

Podcast: Diversity, Equity, and Inclusion Measures Continue to Evolve in the Clinical Space

Listen to expert perspectives from Tracey Parker, Vice President, Biometrics, Advanced Clinical and Rebecca Starkie, Senior Global Patient Engagement Director, Advanced Clinical on the recent history of DEI in clinical trials and the barriers to patient participation. Examine the key drivers that have influenced the development of diversity, equity, and inclusion programs for clinical trials.

Table

View full table

Topics

Tags:
BioPharmaceutical United States Reimbursement
Latest Headlines

EU Multistakeholder Project Aims To Give eConsent The ‘Place It Deserves’

EU Regulatory Reforms Mean Many Orphan Drug Producers Won’t Benefit From Incentives

Canada Proposes List Of ‘Critical Products’ & More Agile Regulation To Address Shortages

Third Time’s A Charm? US FDA Once Again Proposes Mandatory Consumer Rx Info

See All
UsernamePublicRestriction

Register

PS079604

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By